Healthy Adults Needed for Beryllium Disease Study
Trial Objectives
Chronic beryllium disease (CBD) is caused by inhaling beryllium dust and fumes into the lungs. People with exposure can develop a response to beryllium similar to an allergy which can lead to scars in the lungs and breathing problems.
The goal of this study is to understand how certain white blood cells called macrophages function in the development of CBD. By collecting lung and blood samples from healthy adults, our researchers can learn more about the cells involved in the development of scarring lung diseases and ultimately target new treatment therapies.
Who Can Participate
Healthy, nonsmoking adults with no prior history of respiratory or autoimmune disease who are able to undergo a blood draw and a bronchoscopy.
Age: 18-80 Gender: Any
Estimated Time Commitment
5 hours over 2 visits
Time Commitment Details
During the first visit, participants give consent and receive physical exam. Second visit includes bronchoalveolar lavage and blood draw. The second visit will last approximately four hours.
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Not Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
National Institutes of Health
Principal Investigators
Li Li, MD, PhD
Co-Investigators
Lisa A. Maier, MD, MSPH, FCCP, ATSF